Trials / Recruiting
RecruitingNCT07260708
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
A Phase I Clinical Study to Evaluate The Safety and Pharmacokinetics of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2922 injection (subcutaneous injection) | TQB2922 is a bispecific antibody against Epidermal Growth Factor Receptor (EGFR)/c-Met. |
Timeline
- Start date
- 2025-12-16
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-12-03
- Last updated
- 2025-12-19
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07260708. Inclusion in this directory is not an endorsement.